Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

ABSTRACT: The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists

DISEASE(S): Lung Squamous Cell Cancer,Triple Negative Breast Neoplasms,Melanoma,Head And Neck Squamous Cell Cancer,Triple Negative Breast Cancer,Pancreatic Cancer,Neoplasms, Squamous Cell,Carcinoma, Squamous Cell,Braf Mutant Colorectal Cancer,Colorectal Neoplasms,Cervical Squamous Cell Cancer,Esophageal Squamous Cell Cancer,Esophageal Squamous Cell Carcinoma

PROVIDER: 2106471 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Project description:The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.

| 2189885 | ecrin-mdr-crc

A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

Project description:This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors with HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard therapy or for which no standard therapy exists, particularly urothelial cancer, biliary tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.

| 2264167 | ecrin-mdr-crc

Photodynamic oncolytic virus therapy for central nervous system malignancies

Project description:Photodynamic oncolytic virus therapy for central nervous system malignancies

| PRJNA923791 | ENA

Early Onset Malignancies Initiative

Project description:Early Onset Malignancies Initiative

| PRJNA597502 | ENA

Early Onset Malignancies Initiative

Project description:Early Onset Malignancies Initiative

| PRJNA597501 | ENA

Proteomic characterization of cerebrospinal fluid in patients with brain malignancies

Project description:Recent technological advances in molecular diagnostics through liquid biopsies hold the promise to monitor tumor evolution and treatment response of brain malignancies without the need of invasive surgical tissue accrual. Here, we implemented a new mass spectrometry-based protein analysis pipeline and analyzed 251 cerebrospinal fluid (CSF) samples from patients with four types of brain malignancies (glioblastoma, lymphoma, brain metastasis and meningeal disease) as well as from healthy individuals. On average, we identified 511 ± 121 proteins per CSF sample. 169 proteins were commonly deregulated in all four types of brain malignancies compared to controls. CSF analysis of glioblastoma patients identified two proteomic clusters that correlated with tumor size and patient survival. By integrating CSF data with proteomic analyses of matching glioma tumor tissue and primary glioma cells, we identified potential CSF biomarkers for glioblastoma, in particular chitinase-3-like protein 1 (CHI3L1) and glial fibrillary acidic protein (GFAP). Results were validated in a prospective cohort with 35 glioblastoma patients. Response of a patient with meningeal disease to combinatorial drug treatment was associated with a complex shift of the proteomic signature, including detection of potential drug resistance mechanisms. Therefore, proteomic analysis of CSF in brain malignancies has the potential to reveal biomarkers for diagnosis and therapy monitoring.

2021-03-25 | PXD021984 | Pride

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Project description:This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin’s lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom’s macroglobulinemia. This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.

| 2040617 | ecrin-mdr-crc

MGH Gastrointestinal Malignancies Resistance Initiative

Project description:MGH Gastrointestinal Malignancies Resistance Initiative

| PRJNA550215 | ENA

MGH Gastrointestinal Malignancies Resistance Initiative

Project description:MGH Gastrointestinal Malignancies Resistance Initiative

| PRJNA550216 | ENA